M

Magle Chemoswed Holding AB
STO:MAGLE

Watchlist Manager
Magle Chemoswed Holding AB
STO:MAGLE
Watchlist
Price: 34 SEK Market Closed
Market Cap: 667.4m SEK
Have any thoughts about
Magle Chemoswed Holding AB?
Write Note

Magle Chemoswed Holding AB
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Magle Chemoswed Holding AB
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
M
Magle Chemoswed Holding AB
STO:MAGLE
Income from Continuing Operations
kr12.2m
CAGR 3-Years
89%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Income from Continuing Operations
kr192m
CAGR 3-Years
-28%
CAGR 5-Years
8%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Income from Continuing Operations
-kr1.7B
CAGR 3-Years
-226%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Income from Continuing Operations
kr257m
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
17%
G
Genovis AB
STO:GENO
Income from Continuing Operations
kr17.3m
CAGR 3-Years
14%
CAGR 5-Years
30%
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Income from Continuing Operations
kr229m
CAGR 3-Years
43%
CAGR 5-Years
38%
CAGR 10-Years
29%
No Stocks Found

Magle Chemoswed Holding AB
Glance View

Market Cap
667.4m SEK
Industry
Life Sciences Tools & Services

Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

MAGLE Intrinsic Value
85.22 SEK
Undervaluation 60%
Intrinsic Value
Price
M

See Also

What is Magle Chemoswed Holding AB's Income from Continuing Operations?
Income from Continuing Operations
12.2m SEK

Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Income from Continuing Operations amounts to 12.2m SEK.

What is Magle Chemoswed Holding AB's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
89%

Over the last year, the Income from Continuing Operations growth was 33%. The average annual Income from Continuing Operations growth rates for Magle Chemoswed Holding AB have been 89% over the past three years .

Back to Top